.

Revance Therapeutics reported $396.1M in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
ALKERMES ALKS:US $ 294.54M 0.63M
Bristol Myers Squibb BMY:US $ 42060M 2912M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 196.04M 224.42M
Eli Lilly And LLY:US $ 16813.8M 305M
Endo International Ordinary Shares ENDP:US $ 8065.3M 25.32M
Horizon Pharma HZNP:US $ 2566.99M 1.75M
JAZZ PHA JAZZ:US $ 6021M 2.87M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Pacira Pharmaceuticals PCRX:US $ 755.65M 167.77M
Procter & Gamble PG:US $ 31493M 2176M
Revance Therapeutics RVNC:US $ 396.1M 53.64M
Supernus Pharmaceuticals SUPN:US $ 400.91M 0.53M
Teva Pharmaceutical Industries TEVA:US $ 22082M 835M